Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Minimal residual disease guided maintenance with belantamab mafodotin and lenalidomide after transplant in newly diagnosed myeloma

Phase 2 trial of MRD-guided post-transplant maintenance. The registry primary outcome is conversion from MRD-positive to MRD-negative complete response. ClinicalTrials.gov lists the study as recruiting.

M.D. Anderson Cancer Center